Endometriosis-associated ovarian cancer is a single entity with distinct clinicopathological characteristics
Open accessAbstract
Objective: To compare the clinicopathological features and chemotherapy response of ovarian clear cell carcinoma (CCC) and endometrioid carcinoma (EC) associated with endometriosis or not.Methods: This was a retrospective study of 128 patients diagnosed with CCC and EC from 2002 to 2017. Clinicopathological features and chemotherapy response were analyzed.Results:There were 34 women with endometriosis-associated ovarian cancer (EAOC) and 94 with non-endometriosis associated ovarian cancer (non-EAOC) according to Sampson’s and Scott’s criteria. The mean diagnosis age in the EAOC group was 48.65 vs. 54.39 years in non-EAOC (p = 0.002). Compared with non-EAOC, the EAOC patients were more likely to have an earlier menarche age (13 vs. 14 years, p = 0.001), a higher incidence of infertility (26.47% vs. 10.64%, p = 0.026), and an earlier stage tumor (91.18% vs. 73.40% in stages I–II, p = 0.032). At a median follow-up time of 32.9 months, overall survival among patients with EAOC was significantly longer (109.8 vs. 47.4 months, p = 0.007). Association with endometriosis (p = 0.033) was the significant favorable prognostic factors associated with survival. However, stratifying by stage, the overall survival advantage of EAOC was not significant. Although EAOC had a better prognosis, no difference was observed in chemotherapy response between the two groups (p = 0.535).Conclusions: The EAOC patients were often diagnosed at a younger age, an earlier stage, and related to nulliparity and infertility. Patients with EAOC had a better prognosis than non-EAOC, early stage rather than association with endometriosis may be the driver of survival.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Adjuvant chemotherapies were mostly taxane-carboplatin regimens, as this is the standard treatment for epithelial ovarian cancer, which was adapted to endometriosis-associated ovarian cancer.
“Adjuvant chemotherapies were mostly taxane–carboplatin regimens, as this is the standard treatment for epithelial ovarian cancer, which was adapted to endometriosis-associated ovarian cancer [59].”
From Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review (2024) · cites this paper as [59]
The Discussion (page unavailable) calls intravenous taxane–carboplatin the standard recommended postoperative treatment for epithelial ovarian cancer. Patients and methods (page unavailable) says most patients received platinum-based chemotherapy after surgery, but does not establish that most received taxane–carboplatin specifically or explicitly describe its adaptation to endometriosis-associated ovarian cancer. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 39 · Cited by 30
Research works printed but not linked: 1
- Kim HS, Chung HH, Kim JW, Park NH, Song YS. ISO-4-1 Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis(group 4 oncology 2,IS Award Candidate, International Session). J Bacteriol. 2001;182:6975-6982.
- Authors
- Li, Q., Sun, Y., Zhang, X., Wang, L., Wu, W., Wu, M., Meng, C., & Liu, G.
- Affiliations
- Affiliated Hospital of Hebei University (CN)
- Tianjin Medical University General Hospital (CN)
- Corresponding author
- Liu, Guoyan
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2019-03-26
- Volume
- 20
- Issue
- 7
- Pages
- 1029-1034
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- PMC
- PMC6605994
- OpenAlex
- W2924316731
- Cited by
- 30
- References
- 39
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 8 · 2023: 6 · 2022: 4 · 2021: 1 · 2020: 1 · 2019: 1
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Biology & Therapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81472761)
- Natural Science Foundation of Tianjin City (14JCYBJC25300)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- endometriosis-associated ovarian cancer, ovarian clear cell carcinoma, endometrioid carcinoma, clinicopathological features, chemotherapy response, overall survival, infertility, early menarche, tumor stage, prognostic factors, nulliparity
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Disease Susceptibility, Endometriosis, Female, Humans, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Prognosis, Proportional Hazards Models, Drug Resistance, Neoplasm, Kaplan-Meier Estimate, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
